A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors

Solid Tumors Clinical Trial

Official title:

A Pilot Study of Lyso-thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox®) and Magnetic Resonance-Guided High Intensity Focused Ultrasound (MR-HIFU) for Treatment of Relapsed or Refractory Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04791228
• Other study ID #: HIFU Thermodox PII
• Status: Recruiting
• Phase: Phase 2
• Start date: November 10, 2022
• Est. completion date: December 1, 2025

Study information

• Verified date: August 2023
• Source: Children's National Research Institute
• Contact: General HIFU trials
• Phone: 202-476-5522
• Email: HIFUtrials[@]childrensnational.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a pilot study of LTLD with MR-HIFU hyperthermia followed by ablation in subjects with refractory/relapsed solid tumors.

Description:

LTLD is a heat-activated formulation of liposomal doxorubicin that releases the drug when exposed to hyperthermic conditions (40-45°C). This novel agent has been well tolerated in adults with similar toxicity profile to doxorubicin. MR-HIFU offers a non-invasive and non-ionizing ability to selectively heat large tissue volumes. Thus, MR-HIFU is a promising technology for triggering doxorubicin release from LTLD. The investigator's approach involves continuous maintenance of the target at mild hyperthermia with MR-HIFU following LTLD infusion. Following hyperthermia, the investigators will deliver ablation therapy (>55°C) to targeted areas of tumor where feasible and safe. Addition of this ablation therapy after mild-hyperthermia-triggered drug delivery with LTLD has the potential to significantly potentiate chemotherapy with minimal additional adverse effects to improve local control and drug delivery without increasing toxicity.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 14
• Est. completion date: December 1, 2025
• Est. primary completion date: December 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• AGE: = 12 years of age.

• DIAGNOSIS: Histologically confirmed malignant solid tumors

• TUMOR LOCATION: Patient must have at least one tumor located in areas accessible to HIFU, which will be defined as the target lesion(s). Target lesions must be reachable within the normal safety margins of HIFU as specified in the instructions for use.

• TARGET LESION(S): Radiographically measurable/evaluable solid tumor target lesion(s).

• THERAPEUTIC OPTIONS:

• Malignant Tumor: The patient's cancer must have relapsed after or failed to respond to frontline curative therapy and there must not be other potentially curative treatment options available.

• PRIOR THERAPY:

• Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering on this study.

• No limitation on the number of prior chemotherapy regimens that the patient may have received prior to study entry.

• Myelosuppressive chemotherapy: The last dose of all myelosuppressive anticancer drugs must be at least 3 weeks prior to study entry (6 weeks for prior nitrosoureas) Prior treatment with anthracyclines is allowed as long as total cumulative dose is = 450 mg/m2.

• Immunotherapy: The last dose of immunotherapy (monoclonal antibody or vaccine) must be at least 3 weeks prior to study entry.

• Biologic (anti-cancer agent): The last dose of all biologic agents for the treatment of the patient's cancer (such as retinoids or tyrosine kinase inhibitors) must be at least 7 days prior to study entry.

• Radiation therapy: The last dose of radiation to more than 25% of marrow containing bones (pelvis, spine, skull) must be at least 4 weeks prior to study entry. The last dose of all other local palliative (limited port) radiation must be at least 2 weeks prior to study entry.

• Stem Cell Transplantation. At least 42 days post-autologous stem cell transplant or at least 90 post-allogeneic transplant and recovered from toxicities without evidence of graft versus host disease and on stable doses of immunosuppressive medications if required.

• Growth Factors. The last dose of colony stimulating factors, such as filgrastim, sargramostim, and erythropoietin, must be at least 1 week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be at least 2 weeks prior to study entry.

• CONCURRENT THERAPIES:

• No other anti-cancer therapy (chemotherapy, biological therapy, radiation therapy) is permitted.

• PERFORMANCE STATUS:

• Lansky/Karnofsky performance level = 50% (See Appendix I).

• Patients who are unable to walk because of paralysis or motor weakness, but who are up in a wheelchair will be considered ambulatory for the purpose of calculating the performance score.

• HEMATOLOGIC FUNCTION:

• Peripheral absolute neutrophil count (ANC) of = 1000/µL.

• Platelet count = 75,000/µL (transfusion independent (no transfusion within at least 7 days prior to enrollment)).

• HEPATIC FUNCTION:

• Total bilirubin must be = 1.5 times the upper limit of normal (ULN) for age and gender.

• SGPT (ALT) must be = 3.0 times the upper limit of normal for age.

• RENAL FUNCTION: Serum creatinine = ULN for age/sex OR a creatinine clearance =60 mL/min/1.73 m2.

• CARDIAC FUNCTION: Adequate Cardiac Function with Ejection Fraction > 50% by echocardiogram.

Exclusion Criteria:

• Clinically significant unrelated systemic illness, such as serious infections, hepatic, renal or other organ dysfunction, which in the judgment of the Principal or Associate Investigator would compromise the patient's ability to tolerate study interventions.

• Patients who are pregnant or breast-feeding are not eligible for this study due to risks of fetal and teratogenic adverse events seen in animal/human studies with doxorubicin. Negative pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method beginning at the signing of informed consent and until at least 30 days after the last dose of study drug. The definition of adequate contraception will be based on the judgment of the principal investigator or designated associate.

• Implant or prosthesis within the path of the HIFU beam.

• Target pathway <1 cm from nerve plexus, spinal canal, or bowel.

• Target lesion in the skull.

• Inability to undergo MRI and/or contraindication for MRI.

• Inability to tolerate stationary position during HIFU.

• Previous history of hypersensitivity to doxorubicin or its liposomal formulations.

• Patients currently receiving other anticancer agents.

• Patients currently receiving other investigational agents.

Related Conditions & MeSH terms

• Bone Metastases
• Carcinoma
• Ewing Sarcoma
• Germ Cell Tumor
• Hepatic Tumor
• Malignant Epithelial Neoplasm
• Neoplasms
• Neoplasms, Glandular and Epithelial
• Rhabdomyosarcoma
• Sarcoma
• Sarcoma, Ewing
• Soft Tissue Sarcoma
• Solid Tumors
• Wilms Tumor

Intervention

Device:
• Magnetic Resonance-Guided High Intensity Focused Ultrasound
Magnetic resonance (MR)-guided high intensity focused ultrasound (HIFU) provides precise and controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator without the need for a scalpel or needle. Additional therapeutic advantages of this modality include its range of bioeffects, including both high temperature tumor ablation via coagulative necrosis, and effects of lower temperature, mild hyperthermia that can help to enhance local drug delivery to tumors. Both tumor ablation and hyperthermia may be employed to potentiate the effects of chemotherapy.

Drug:
• Lyso-thermosensitive Liposomal Doxorubicin
LTLD combines doxorubicin with lyso-thermosensitive liposomes that can selectively deliver drug to tumors and when exposed to temperatures greater than 40°C, rapidly and locally releases doxorubicin in high concentrations from systemically administered LTLD. If combined with hyperthermia, doxorubicin will be released in the heated tumor margins and in any areas within the tumor that were not completely ablated and increase the likelihood of complete tumor necrosis. LTLD will extend tumor cell death to the hyperthermic regions in the peri-ablation zones and minimize the possibility of incomplete ablation or tumor recurrence.

Locations

Country	Name	City	State
United States	Children's National Hospital	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Children's National Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Exploratory objective 1: Response of non-target lesion(s) assessed by CT or MRI	Lesions that are evaluable or measurable but not in the treated location(s) will be collected	At the end of every 21-day cycle
Other	Exploratory objective 2: Participant reported target tumor pain intensity assessed using the Numerical Rating Scale-11 (NRS-11)	The NRS-11 consists of a 11-point numeric scale to assess pain intensity from 0 (no pain) to 10 (worst pain)	At the end of every 21-day cycle
Other	Exploratory objective 3: Participant reported impact of pain on daily activities assessed using the PROMIS Pain Interference Scale (PROMIS-PI)	The PROMIS-PI consists of 8 questions on pain. Each question will be rated from 0 (never), 1 (almost never), 2 (sometimes), 3 (often), and 4 (almost always)	At the end of every 21-day cycle
Other	Exploratory objective 4: Blood samples taken to see adaptive immune response and immune suppression	To determine changes in pharmacodynamics of immune markers	At 1 day and 1 week after MR-HIFU treatment on first 21-day cycle
Primary	Primary objective 1: Response of treated target lesion(s) assessed by CT or MRI	The Response Evaluation Criteria in Solid Tumors (RECIST v1.1) will be used	At the end of every 21-day cycle
Primary	Primary objective 2: The number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria of Adverse Events (CTCAE) v.5	CTCAE v.5 will be used	Up to thirty days after last dose of protocol therapy